|
Mr. Schor has more than 10 years of experience in biotechnology, business development and private equity. Mr. Schor leads corporate and business development initiatives including oversight and establishment of strategic collaborations for EPIX programs and assets and strategic planning activities. Mr. Schor has led the formation and negotiations of EPIX’s collaborations with Amgen, GlaxoSmithKline and Cystic Fibrosis Foundation Therapeutics. Prior to joining EPIX, Mr. Schor served as Partner, Life Sciences at Yozma Venture Capital, managing the fund’s healthcare practice. Mr. Schor was one of the lead investors in Predix Pharmaceuticals Ltd. when the company incorporated in 2000 and subsequently contributed to the merger between EPIX and Predix. Mr. Schor previously held positions at Arthur Anderson and BDO consultants and holds an MBA, B.A. in biology, B.A. in economics and is a Certified Public Accountant (CPA). | 